Business Standard

NCLT approves the demerger of Piramal Enterprises' pharma business

This paves the way towards creation of two sepa­ra­te listed entities - Piramal Enter­prises and Piramal Pharma

Piramal Enterprises
Premium

Photo: Shutterstock

BS Reporter
The NCLT on Friday approved the demerger of Piramal Enterprises’ pharma business with the parent firm now retaining the financial ser­vices business. 

This paves the way towards creation of two sepa­ra­te listed entities — Piramal Enter­prises and Piramal Pharma. “The approval... is a significant miles­tone. We are on track to achieve the completion of demerger and separate listing of Piramal Pharma by the third quarter,” Ajay Piramal, chairman, Piramal Ente­r­p­rises, said in a statement. 

The Board had approved the demerger in October last year and the company later obtained consent from the RBI, SEBI, stock exchanges, and clearances from  creditors and equity

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in